Next Era of Alzheimer's Care Will be Defined by Precision Prevention
NEW YORK, July 28, 2025 /PRNewswire/ -- Results from the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) released today strengthen the case for precision prevention, a strategy set to revolutionize Alzheimer's care by combining lifestyle changes with targeted therapeutics based on individual risk factors.
"The future lies in precision prevention," said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the Alzheimer's Drug Discovery Foundation. "We have seen this model succeed in cancer and heart disease, and with a growing body of evidence showing neither lifestyle nor drugs can stop Alzheimer's alone, now is the time to double down on studying the two in combination, which will lay the path for precision medicine."
The ADDF is driving a new era of clinical trials that look at lifestyle and therapeutic interventions in tandem, including Dr. Miia Kivipelto's MET-FINGER study, which has created a blueprint for combination therapy studies going forward.
The U.S. POINTER study, released during the Alzheimer's Association International Conference (AAIC) and published simultaneously in the Journal of the American Medical Association (JAMA), found multidomain lifestyle interventions supported cognitive health in aging populations. This builds on previous findings from Dr. Miia Kivipelto's original FINGER trial, the first to show the critical role of lifestyle changes in preventing dementia.
U.S. POINTER showed its structured high-intensity lifestyle interventions benefitted participants regardless of their APOE4 carrier status, a genetic risk factor for Alzheimer's disease. This contrasts findings from the FINGER study, which showed benefit especially in carriers of APOE4, and further highlights the wide-reaching impacts of lifestyle changes.
"The U.S. POINTER results validate the findings of the FINGER study in a more diverse U.S. population," said Dr. Kivipelto. "This is yet another proof point that lifestyle can have a tremendous impact on the brain. By developing personalized scientific approaches to match each patient's unique biomarker profile with a combined drug and prevention plan, we are redefining how we treat and prevent Alzheimer's."
About The Alzheimer's Drug Discovery Foundation (ADDF)Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the development of drugs to prevent, treat, and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug development, biomarker, and prevention programs in 21 countries. To learn more, please visit: http://www.alzdiscovery.org/.
View original content to download multimedia:https://www.prnewswire.com/news-releases/next-era-of-alzheimers-care-will-be-defined-by-precision-prevention-302515145.html
SOURCE Alzheimer's Drug Discovery Foundation
Inicia sesión para acceder a tu cartera de valores
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@
Yahoo
4 hours ago
- Yahoo
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a rare condition called Duchenne muscular dystrophy — to patients who can walk. U.S. shipments to patients who cannot walk independently are still halted, following the death of two teenage boys earlier this year. These incidents brought heightened regulatory scrutiny to Sarepta in recent weeks, while the pause of shipments raised concerns about the future of Elevidys — the company's largest revenue generator. Sarepta's announcement followed the U.S. Food and Drug Administration's recommendation that the voluntary hold on shipments be removed after a probe showed the death of an 8-year-old boy in Brazil was not related to Elevidys. Wall Street analysts said the resumption of shipments would allow Sarepta to fulfill its near-term payments to partner Arrowhead and maintain access to its debt facilities. "The FDA's recommendation and the resumption of commercial treatment in the U.S. virtually eliminate the risk of Elevidys being formally withdrawn from the market," said William Blair analyst Sami Corwin. While the decision allows some patients to regain access to the treatment, analysts warned that patients and doctors could show hesitancy in light of the recent hit to reputation. "It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term," Corwin said. Sarepta's partner Roche had also stopped Elevidys shipments in certain countries outside the U.S. Shares of Sarepta surged 36% to $18.85 in premarket trading. They have fallen more than 80% since the first Elevidys-related death was reported in March. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
CNET
4 hours ago
- CNET
What Is Superintelligence? Everything You Need to Know About AI's Endgame
You've probably chatted with ChatGPT, experimented with Gemini, Claude or Perplexity, or even asked Grok to verify a post on X. These tools are impressive, but they're just the tip of the artificial intelligence iceberg. Lurking beneath is something far bigger that has been all the talk in recent weeks: artificial superintelligence. Some people use the term "superintelligence" interchangeably with artificial general intelligence or sci-fi-level sentience. Others, like Meta CEO Mark Zuckerberg, use it to signal their next big moonshot. ASI has a more specific meaning in AI circles. It refers to an intelligence that doesn't just answer questions but could outthink humans in every field: medicine, physics, strategy, creativity, reasoning, emotional intelligence and more. We're not there yet, but the race has already started. In July, Zuckerberg said during an interview with The Information that his company is chasing "personal superintelligence" to "put the power of AI directly into individuals' hands." Or, in Meta's case, probably in everyone's smart glasses. Scott Stein/CNET That desire kicked off a recruiting spree for top researchers in Silicon Valley and a reshuffling inside Meta's FAIR team (now Meta AI) to push Meta closer to AGI and eventually ASI. So, what exactly is superintelligence, how close are we to it, and should we be excited or terrified? Let's break it down. What is superintelligence? Superintelligence doesn't have a formal definition, but it's generally described as a hypothetical AI system that would outperform humans at every cognitive task. It could process vast amounts of data instantly, reason across domains, learn from mistakes, self-improve, develop new scientific theories, write flawless code, and maybe even make emotional or ethical judgments. The idea became popularized through philosopher Nick Bostrom's 2014 book Superintelligence: Paths, Dangers, Strategies , which warned of a scenario where an AI bot becomes smarter than humans, self-improves rapidly and then escapes our control. That vision sparked both excitement and fear among tech experts. Speaking to CNET, Bostrom says many of his 2014 warnings "have proven quite prescient." What has surprised him, he says, is "how anthropomorphic current AI systems are," with large language models behaving in surprisingly humanlike ways. Bostrom says he's now shifting his attention toward deeper issues, including "the moral status of digital minds and the relationship between the superintelligence we build with other superintelligences," which he refers to as "the cosmic host." For some, ASI represents the pinnacle of progress, a tool to cure disease, reverse climate change and crack the secrets of the universe. For others, it's a ticking time bomb -- one wrong move and we're outmatched by a machine we can't control. It's sometimes called the last human invention, not because it's final, but because ASI could invent everything else we need. British mathematician Irving John Good described it as an "intelligence explosion." Superintelligence doesn't exist yet. We're still in the early stages of what's called artificial narrow intelligence. It's an AI system that is great at specific tasks like translation, summarization and image generation, but not capable of broader reasoning. Tools like ChatGPT, Gemini, Copilot, Claude and Grok fall into this category. They're good at some tasks, but still flawed, prone to hallucinations and incapable of true reasoning or understanding. To reach ASI, AI needs to first pass through another stage: artificial general intelligence. What is AGI? AGI, or artificial general intelligence, refers to a system that can learn and reason across a wide range of tasks, not just one domain. It could match human-level versatility, such as learning new skills, adapting to unfamiliar problems and transferring knowledge across fields. Unlike current chatbots, which rely heavily on training data and struggle outside of predefined rules, AGI would handle complex problems flexibly. It wouldn't just answer questions about math and history; it could invent new solutions, explain them and apply them elsewhere. Current models hint at AGI traits, like multimodal systems that handle text, images and video. But true AGI requires breakthroughs in continual learning (updating knowledge without forgetting old stuff) and real-world grounding (understanding context beyond data). And none of the major models today qualify as true AGI, though many AI labs, including OpenAI, Google DeepMind and Meta, list it as their long-term target. Once AGI arrives and self-improves, ASI could follow quickly as a system smarter than any human in every area. How close are we to superintelligence? A superintelligent future concept I generated using Grok AI. Grok / Screenshot by CNET That depends on who you ask. A 2024 survey of 2,778 AI researchers paints a sobering picture. The aggregate forecasts give a 50% chance of machines outperforming humans in every possible task by 2047. That's 13 years sooner than a 2022 poll predicted. There's a 10% chance this could happen as early as 2027, according to the survey. For job automation specifically, researchers estimate a 10% chance that all human occupations become fully automatable by 2037, reaching 50% probability by 2116. Most concerning, 38% to 51% of experts assign at least a 10% risk of advanced AI causing human extinction. Geoffrey Hinton, often called the Godfather of AI, warned in a recent YouTube podcast that if superintelligent AI ever turned against us, it might unleash a biological threat like a custom virus -- super contagious, deadly and slow to show symptoms -- without risking itself. Resistance would be pointless, he said, because "there's no way we're going to prevent it from getting rid of us if it wants to." Instead, he argued that the focus should be on building safeguards early. "What you have to do is prevent it ever wanting to," he said in the podcast. He said this could be done by pouring resources into AI that stays friendly. Still, Hinton confessed he's struggling with the implications: "I haven't come to terms with what the development of superintelligence could do to my children's future. I just don't like to think about what could happen." Factors like faster computing, quantum AI and self-improving models could accelerate things. Hinton expects superintelligence in 10 to 20 years. Zuckerberg said during that podcast that he believes ASI could arrive within the next two to three years, and OpenAI CEO Sam Altman estimates it'll be somewhere in between those time frames. Most researchers agree we're still missing key ingredients, like more advanced learning algorithms, better hardware and the ability to generalize knowledge like a human brain. IBM points to areas like neuromorphic computing (hardware inspired by human neurons), evolutionary algorithms and multisensory AI as building blocks that might get us there. Meta's quest for 'personal superintelligence' Meta launched its Superintelligence Labs in June, led by Alexandr Wang (ex-Scale AI CEO) and Nat Friedman (ex-GitHub CEO), with $14.3 billion invested in Scale AI and $64 billion to $72 billion for data centers and AI infrastructure. Zuckerberg doesn't shy away from Greek mythology, with names like Prometheus and Hyperion for his two AI data superclusters (massive computing centers). He also doesn't talk about artificial superintelligence in abstract terms. Instead, he claims that Meta's specific focus is on delivering "personal super intelligence to everyone in the world." This vision, according to Zuckerberg, sets Meta apart from other research labs that he says primarily concentrate on "automating economically productive work." Bostrom thinks this isn't mere hype. "It's possible we're only a small number of years away from this," he said of Meta's plans, noting that today's frontier labs "are quite serious about aiming for superintelligence, so it is not just marketing moves." Though still in its early stages, Meta is actively recruiting top talent from companies like OpenAI and Google. Zuckerberg explained in his interview with The Information that the market is extremely competitive because so few people possess the requisite high level of skills. Facebook and Zuckerberg didn't respond to requests for comment. Should humans subscribe to the idea of superintelligent AI? There are two camps in the AI world: those who are overly enthusiastic, inflating its benefits and seemingly ignoring its downsides; and the doomers who believe AI will inevitably take over and end humanity. The truth probably lands somewhere in the middle. Widespread public fear and resistance, fueled by dystopian sci-fi and very real concerns over job loss and massive economic disruption, could slow progress toward superintelligence. One of the biggest problems is that we don't really know what even AGI looks like in machines, much less ASI. Is it the ability to reason across domains? Hold long conversations? Form intentions? Build theories? None of the current models, including Meta's Llama 4 and Grok 4, can reliably do any of this. There's also no agreement on what counts as "smarter than humans." Does it mean acing every test, inventing new math and physics theorems or solving climate change? And even if we get there -- should we? Building systems vastly more intelligent than us could pose serious risks, especially if they act unpredictably or pursue goals misaligned with ours. Without strict control, it could manipulate systems or even act autonomously in ways we don't fully understand. Brendan Englot, director of the Stevens Institute for Artificial Intelligence, shared with CNET that he believes "an important first step is to approach cyber-physical security similarly to how we would prepare for malicious human-engineered threats, except with the expectation that they can be generated and launched with much greater ease and frequency than ever before." That said, Englot isn't convinced that current AI can truly outpace human understanding. "AI is limited to acting within the boundaries of our existing knowledge base," Englot tells CNET. "It is unclear when and how that will change." Regulations like the EU AI Act aim to help, but global alignment is tricky. For example, China's approach differs wildly from the West's. Trust is one of the biggest open questions. A superintelligent system might be incredibly useful, but also nearly impossible to audit or constrain. And when AI systems draw from biased or chaotic data like real-time social media, those problems compound. Some researchers believe that given enough data, computing power and clever model design, we'll eventually reach AGI and ASI. Others argue that current AI approaches (especially LLMs) are fundamentally limited and won't scale to true general or superhuman intelligence because the human brain has 100 trillion connections. That's not even accounting for our capability of emotional experience and depth, arguably humanity's strongest and most distinctive attribute. But progress moves fast, and it would be naive to dismiss ASI as impossible. If it does arrive, it could reshape science, economics and politics -- or threaten them all. Until then, general intelligence remains the milestone to watch. If and when superintelligence does become a reality, it could profoundly redefine human life itself. According to Bostrom, we'd enter what he calls a "post-instrumental condition," fundamentally rethinking what it means to be human. Still, he's ultimately optimistic about what lies on the other side, exploring these ideas further in his most recent book, Deep Utopia. "It will be a profound transformation," Bostrom tells CNET.
